<DOC>
	<DOCNO>NCT00566033</DOCNO>
	<brief_summary>Test whether intensive intervention improve renal cardiovascular outcome patient chronic renal insufficiency . Test whether multi-method intensive intervention include clinical Audit improve adherence series quality indicator relevant hypertension control , proteinuria , treatment dyslipidemia , anemia , calcium phosphate alteration patient chronic renal insufficiency .</brief_summary>
	<brief_title>Multiple Intervention AUdit Renal Diseases Optimize Care</brief_title>
	<detailed_description>Background : Guidelines currently promote mean link evidence base medicine clinical practice reduce variation clinical practice ( 1 ) . However , ample evidence implementation evidence-based recommendation prevention management renal disease progression associate cardiovascular complication remain largely unsatisfactory ( 2 ) . Deficiencies exist treatment dyslipidemia hypertension , inadequate use angiotensin-converting enzyme inhibitor angiotensin receptor blocker well treatment anemia alteration calcium phosphate metabolism ( 2 ) . Furthermore patient diabetes mellitus infrequently receive recommend treatment elevate glycosylated haemoglobin level , hypertension , dyslipidemia . The importance intervention increase adherence practice guideline improve disease control widely perceive . However , little known relative effectiveness different implementation strategy . Fresh research require develop validate practical strategy improve provision evidence-based medicine nephrology clinic . In particular , study address multiple common , chronic condition simultaneously affect population patient chronic renal insufficiency felt primary importance . The study approve Ethical Committees Nephrology Units participate MAURO study . Specific hypothesis : This study design clinical trial aim assess whether quality improvement intervention effective standard care improve adherence series quality indicator relevant prevention renal disease progression associate cardiovascular complication . The multi-method quality improvement intervention ( intensive intervention ) add telephone e-mail contact ( quality improvement facilitation ) audit approach periodic guideline dissemination use standard care . Objective ( ) : Test whether intensive intervention improve renal cardiovascular outcome patient chronic renal insufficiency . Test whether intensive intervention improve adherence series quality indicator relevant hypertension control , proteinuria , treatment dyslipidemia , anemia calcium phosphate alteration . Endpoints : The primary end point composite renal cardiovascular end point , i.e . &gt; 30 % decrease GFR , dialysis , transplantation , death cardiovascular event [ ECG document angina myocardial infarction , heart failure , arrhythmia ( atrial fibrillation ) , cerebro-vascular event ( stroke transient ischemic attack ) peripheral vascular disease ] . The renal unit-level outcome percentage performance target achieve . The patient level outcome percentage patient recommend process measure occur . Key Inclusion Criteria : - Average least 2 measurement creatinine &gt; 1.5-4.0 mg/dL ( male ) &gt; 1.3-3.5 mg/dL ( female ) six month run-in period albuminuria &gt; 30 mg/24h least two consecutive visit - Previous diagnosis specific nephropathy - Non acute rapidly evolve renal disease - Age range :18 - 75 year . - Non-transplanted . - Non-pregnant . - Not affected cancer diseases terminal phase . Study Design procedure : Randomized , control clinical trial , renal clinic unit randomization.The two study arm ( multi-intervention include AUDIT v standard care ) inform general aim study keep blind type intervention make [ ( PRospective Blinded Intervention Design ( PROBID ) ] . Drug Dosage , schedule Route Administration : Drugs treatment blood pressure , dyslipidemia , anemia alteration calcium phosphate metabolism administer accord dos recommend guideline promote Italian society Nephrology KDOQI guideline . Study duration : Three year . Sample Size primary end-point : The sample size calculate underlying assumption intracluster correlation coefficient ( ICC ) ( estimate pilot study ) 0.016 . The expected annual rate primary end point ( least 36 % 3 year ) derive previous study ( 3 ) . With background mind , find allocate 330 patient active arm 330 control arm , study 80 % power capture statistically significant ( P &lt; 0.05 , two tail ) 1/3 risk reduction three year ( 36 % vs 24 % ) intensive intervention group . Corollary information : During study serum DNA data-bank create allow test series open question renal disease progression associate cardiovascular complication . Ethical consideration : The protocol conformity declaration Helsinki inform consent ask participant . Nephrology Units participate MAURO study : Reggio Calabria , Melito ( RC ) , Locri ( RC ) , Palmi ( RC ) , Taurianova ( RC ) , Catanzaro ( 2 Units ) , Soverato ( CZ ) , Lamezia ( CZ ) , Cosenza , Lungro ( CS ) , Rossano ( CS ) , S.Giovanni Fiore ( CS ) , Paola ( CS ) , Amantea-Praia Mare ( CS ) , Vibo Valentia-Tropea-Soriano ( VV ) , Crotone , Messina , Catania , Acireale ( CT ) , Sassari , Francavilla ( TA ) . References : 1 . Hayward RS . Clinical practice guideline trial . CMAJ 1997 ; 156:1725-1727 . 2 . De Nicola L , Minutolo R , Chiodini P , Zoccali C , Castellino P , Donadio C , Strippoli M , Casino F , Giannattasio M , Petrarulo F , Virgilio M , Laraia E , Di Iorio BR , Savica V , Conte G ; TArget Blood Pressure LEvels Chronic Kidney Disease ( TABLE CKD ) Study Group . Global approach cardiovascular risk chronic kidney disease : reality opportunity intervention . Kidney Int 2006 ; 69:538-545 . 3 . Sarnak MJ , Greene T , Wang X , Beck G , Kusek JW , Collins AJ , Levey AS.The effect lower target blood pressure progression kidney disease : long-term follow-up modification diet renal disease study.1 : Ann Intern Med 2005 ; 142 : 342-351 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Creatinine &gt; 1.5 4.0 mg/dL ( male ) &gt; 1.33.5 mg/dL ( female ) . Age range :18 75 year Transplanted Pregnant Affected cancer diseases terminal phase Non acute rapidly evolve renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>AUDIT</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Creatinine</keyword>
	<keyword>Multiple intervents</keyword>
	<keyword>Nephrology guideline .</keyword>
</DOC>